These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 7783658)

  • 1. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects.
    Cordido F; Peñalva A; Peino R; Casanueva FF; Dieguez C
    Metabolism; 1995 Jun; 44(6):745-8. PubMed ID: 7783658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity.
    Cordido F; Peñalva A; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1993 Apr; 76(4):819-23. PubMed ID: 8473389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.
    Peñalva A; Carballo A; Pombo M; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1993 Jan; 76(1):168-71. PubMed ID: 8421084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of growth hormone-releasing peptide 1-6 on GH secretion-stimulated by GHRH and pyridostigmine in lambs.
    Rico M; Rueda V; Lorenzo MT; Núñez A; De la Cruz LF
    J Physiol Biochem; 1998 Jun; 54(2):67-76. PubMed ID: 9858126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
    Lee EJ; Nam SY; Kim KR; Lee HC; Cho JH; Nam MS; Song YD; Lim SK; Huh KB
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of cholinergic tone by pyridostigmine reverses the inhibitory effect of corticotropin-releasing hormone on the growth hormone-releasing hormone-induced growth hormone secretion.
    Corsello SM; Tofani A; Della Casa S; Sciuto R; Rota CA; Colasanti S; Bini A; Barini A; Barbarino A
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):113-6. PubMed ID: 1543015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of endogenous cholinergic tone and alpha-adrenergic pathways on growth hormone responses to His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in the dog.
    Muruais J; Peñalva A; Dieguez C; Casanueva FF
    J Endocrinol; 1993 Aug; 138(2):211-8. PubMed ID: 8228729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man.
    Arvat E; Di Vito L; Gianotti L; Ramunni J; Boghen MF; Deghenghi R; Camanni F; Ghigo E
    Metabolism; 1997 Jan; 46(1):83-8. PubMed ID: 9005975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
    Ismail IS; Scanlon MF; Peters JR
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):149-57. PubMed ID: 8094648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects.
    Peñalva A; Muruais C; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1990 Feb; 70(2):324-7. PubMed ID: 2105328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin?
    Peñalva A; Burguera B; Casabiell X; Tresguerres JA; Dieguez C; Casanueva FF
    Neuroendocrinology; 1989 May; 49(5):551-4. PubMed ID: 2566942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyridostigmine enhances, but does not normalise, the GH response to GH-releasing hormone in obese subjects.
    Castro RC; Vieira JG; Chacra AR; Besser GM; Grossman AB; Lengyel AM
    Acta Endocrinol (Copenh); 1990 Mar; 122(3):385-90. PubMed ID: 2109445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone.
    Valcavi R; Zini M; Maestroni GJ; Conti A; Portioli I
    Clin Endocrinol (Oxf); 1993 Aug; 39(2):193-9. PubMed ID: 8370132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients.
    Cordido F; Alvarez-Castro P; Isidro ML; Casanueva FF; Dieguez C
    Eur J Endocrinol; 2003 Aug; 149(2):117-22. PubMed ID: 12887288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulin-dependent diabetes mellitus.
    Villas-Boas Weffort RF; Ramos-Dias JC; Chipoch C; Lengyel AM
    Metabolism; 1997 Jun; 46(6):706-10. PubMed ID: 9186309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging.
    Ghigo E; Goffi S; Arvat E; Nicolosi M; Procopio M; Bellone J; Imperiale E; Mazza E; Baracchi G; Camanni F
    Acta Endocrinol (Copenh); 1990 Aug; 123(2):169-73. PubMed ID: 2220258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.